查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011273

避孕藥市場：按類型、劑型、作用機制、材料類型、使用時長、使用頻率、銷售管道、應用和最終用戶分類－全球市場預測（2026-2032 年）

Contraceptive Market by Type, Formulation, Mode Of Action, Material Type, Duration, Usage Frequency, Sales Channel, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年避孕藥具市場價值為411.3億美元，預計到2026年將成長至441.3億美元，複合年成長率為7.67%，到2032年將達到690.2億美元。

主要市場統計數據
基準年（2025 年） 411.3億美元
預計年份（2026年） 441.3億美元
預測年份（2032年） 690.2億美元
複合年成長率（） 7.67%

從策略角度審視現代避孕現狀，並專注於創新、可及性、監管細微差別和以用戶為中心的優先事項。

避孕市場正處於轉折點，臨床創新、不斷變化的消費者期望以及政策環境的轉變正在重塑產品開發和獲取模式。生物醫學技術和製藥科學的進步正在擴大終端用戶的選擇範圍，而數位健康平台和遠端醫療正在改變避孕方法的發現、處方和獲取方式。同時，關於生殖自主權和包容性的社會討論正在影響需求模式和產品面臨的監管審查。這些趨勢要求價值鏈上的相關人員不僅要考慮有效性和安全性，還要考慮使用者體驗、接受度和公平獲取。

技術、分銷、材料和監管實踐方面的重大系統性變革正在重新定義避孕選擇和交付模式。

過去十年間，技術進步、消費行為以及醫療保健系統優先事項的調整，共同推動了避孕領域的變革，重塑了避孕格局。長效可逆避孕方法在臨床指引和實務上日益受到重視，生產者也更重視產品的持久性、易用性和副作用最小化。同時，荷爾蒙類和非荷爾蒙類避孕方法的進步——包括植入、注射劑、口服藥物、經皮吸收貼片和屏障避孕法——拓寬了治療選擇，並實現了更個人化的護理路徑。

該評估旨在評估主要市場的關稅措施如何重組整個避孕供應鏈的採購、材料選擇、庫存計劃和准入動態。

主要經濟體在2025年徵收關稅，立即對全球避孕藥具及其組件的供應鏈產生了連鎖反應。從受影響地區採購原料和組件的製造商面臨更高的接收成本，被迫迅速調整籌資策略並實現供應商多元化。在許多情況下，契約製造製造商和成品製造商開始評估近​​岸外包、雙重採購安排和庫存策略，以減輕供應鏈中斷的影響。因此，醫院、藥局和電經銷商的前置作業時間和庫存模式都受到了影響。

將產品類型、配方、作用機制、材料和最終用戶概況與可操作的開發和商業策略聯繫起來的精細細分洞察。

細分市場層面的差異化為產品開發和商業策略的優先排序提供了一個切實可行的框架。按類型分類，市場包括：事後緊急避孕藥（分為子宮內避孕器和口服避孕藥）；荷爾蒙療法（包括植入式、注射式、口服和經皮給藥）；非荷爾蒙療法（以屏障避孕法為主）；草藥和自然療法（分為阿育同類療法療法和順勢療法）；以及永久性避孕方法（例如輸卵管結紮術和輸精結紮術）。這些區分揭示了不同的臨床路徑。長效和永久性避孕方法通常需要專科護理和醫療採購，而口服避孕藥、避孕貼片和屏障避孕法則通常涉及更廣泛的基層醫療和零售管道。

區域策略挑戰解釋了監管多樣性、文化規範、製造地和取得模式如何影響全球市場避孕措施的採用。

區域趨勢對產品採納、監管流程和分銷模式有顯著影響。在美洲，都市區先進的臨床應用與農村地區醫療資源分配不均的現狀形成了鮮明對比，這帶來了雙重挑戰：一方面，醫療系統採購方需要投資高效長效的藥物；另一方面，必須透過零售商和線上管道，為更廣泛的人群提供便捷的藥品獲取途徑。支付方方案和公共衛生計畫決定了採購優先事項，而遠端醫療的擴展也不斷改變處方箋和配藥方式。

競爭情報和企業策略揭示了創新、供應鏈韌性和數位服務如何重塑避孕藥開發領域的領導地位。

競爭格局有利於那些能夠整合差異化臨床資產、穩健供應鏈和卓越病患服務的企業。主要企業正投資研發新一代荷爾蒙和非荷爾蒙製劑，加速開發長效製劑，並探索男性專用藥物以拓展目標市場。研發公司、契約製造和分銷合作夥伴之間的策略聯盟日益普遍，這不僅能夠加快規模擴張、拓寬分銷管道，還能降低資本密集度。

高階主管正在採取戰術性和戰略措施，以加強採購、加速材料創新、擴大數位化覆蓋範圍，並根據細分用戶的需求調整產品組合。

產業領導企業應優先考慮幾項協調一致的舉措，以確保短期穩定和長期成長。首先，供應商多元化和製定緊急採購計劃可以降低貿易中斷和關稅波動帶來的風險。雙重採購和投資於經認證的區域供應商將提高營運柔軟性。其次，加速非乳膠材料的開發和商業化可以解決過敏問題，擴大市場吸引力，同時降低單一材料類別的集中風險。第三，拓展數位化管道和遠端醫療夥伴關係可以更好地適應不斷變化的購買行為，並透過整合支援工具提高患者的用藥依從性。

透過嚴格的混合方法研究途徑檢驗了這些見解的有效性，該方法結合了相關人員訪談、文獻整合、供應鏈映射和情境分析。

本分析所依據的研究結合了定性和定量方法，以確保其穩健性和可操作性。主要研究包括對臨床醫生、採購負責人、監管專家和分銷主管進行結構化訪談，以獲取關於臨床應用、採購挑戰和分銷管道趨勢的第一手觀點。此外，還使用了包括同行評審的臨床文獻、監管文件、產品標籤和公開政策文件在內的二手資訊來檢驗臨床和安全性聲明。同時，供應鏈分析繪製了物料流向和製造地圖，以評估貿易政策變化所帶來的風險。

將技術、法規和供應鏈動態的變化轉化為相關人員可操作的策略重點，並得出全面的結論。

總之，避孕市場正經歷一場由技術進步、通路演變、材料創新和政策趨勢共同驅動的重大變革。這些因素共同影響著臨床實務和消費者行為。有效的策略應將臨床差異化與營運韌性相結合，具體包括供應商多元化、在適當情況下採用非乳膠材料，以及整合數位化服務以滿足使用者在各種就醫地點的需求。鑑於區域差異和市場區隔的細微差別，需要採取個人化的方法，既要充分利用全球製造優勢，也要尊重當地的監管環境和文化背景。

目錄

第1章 引言

第2章 分析方法

  • 分析設計
  • 分析框架
  • 市場規模預測
  • 數據三角測量
  • 分析結果
  • 分析的前提條件
  • 分析的局限性

第3章執行摘要

  • 首席體驗長的觀點
  • 市場規模和成長趨勢
  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入（GTM）策略

第5章 市場洞察

  • 消費者分析與最終用戶觀點
  • 消費者體驗基準測試
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第6章：美國關稅的累積影響（2025 年）

第7章：人工智慧（AI）的累積影響（2025 年）

第8章：避孕市場：依類型分類

  • 事後緊急避孕藥
    • IUD
    • 口服避孕藥
  • 荷爾蒙系統
    • 植入式避孕器
    • 注射式避孕藥
    • 口服避孕藥
    • 經皮避孕藥
  • 非荷爾蒙系統
    • 障礙法
    • 草藥避孕
      • 阿育吠陀
      • 同類療法
    • 自然避孕法
  • 永恆的
    • 輸卵管結紮
    • 血管結紮術

第9章：避孕藥市場：以劑型分類

  • 修補
  • 丸
    • 單相型
    • 多相
  • 戒指

第10章：避孕藥市場：依作用機轉分類

  • 植入預防
  • 殺精作用
  • 抑制排卵

第11章：避孕藥具市場：依材質類型分類

  • 基於乳膠
  • 非乳膠
    • 丁腈橡膠
    • 聚異戊二烯
    • 聚氨酯

第12章：避孕藥市場：依持續時間分類

  • 長期
  • 短期

第13章：避孕藥市場：依使用頻率分類

  • 必要時使用
  • 經常使用

第14章 避孕藥市場：依銷售管道分類

  • 離線
    • 醫院藥房
    • 藥局
  • 線上
    • 電子商務平台
    • 網路藥房

第15章 避孕藥市場：依應用領域分類

  • 一般
  • 性交後

第16章 避孕藥市場：依最終用戶分類

  • 女士
    • 青少年
    • 成人
    • 停經後
  • 男性

第17章 避孕藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第18章 避孕藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第19章 避孕藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第20章：美國避孕藥市場

第21章：中國避孕藥市場

第22章 競爭情勢

  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）
  • Abbvie, Inc.
  • Afaxys, Inc.
  • Agile Therapeutics
  • Bayer AG
  • China Resources（Group）Co., LTD.
  • Church & Dwight Co., Inc.
  • Cupid Limited
  • Helm AG
  • Johnson & Johnson Services, Inc.
  • Organon Group of Companies
  • Pfizer Inc.
  • Veru, Inc.
  • Viatris Inc.
Product Code: MRR-4316E4E895C4

The Contraceptive Market was valued at USD 41.13 billion in 2025 and is projected to grow to USD 44.13 billion in 2026, with a CAGR of 7.67%, reaching USD 69.02 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 41.13 billion
Estimated Year [2026] USD 44.13 billion
Forecast Year [2032] USD 69.02 billion
CAGR (%) 7.67%

A strategic orientation to the modern contraceptive environment highlighting innovation, access, regulatory nuance, and user-centric priorities

The contraceptive landscape stands at an inflection point where clinical innovation, shifting consumer expectations, and evolving policy environments converge to reshape product development and access. Advances in biomedical technologies and formulation science are expanding the range of options available to end-users, while digital health platforms and telemedicine are changing how contraception is discovered, prescribed, and obtained. At the same time, societal conversations around reproductive autonomy and inclusivity are influencing both demand patterns and the regulatory scrutiny that products face. These dynamics require stakeholders across the value chain to consider not only efficacy and safety, but also user experience, acceptability, and equity of access.

Transitioning from legacy product portfolios to a future-ready mix requires a deep understanding of clinical differentiation and end-user segmentation. Health systems and payers are emphasizing long-term outcomes and cost-effective care pathways, which in turn affects procurement strategies and formulary decisions. Simultaneously, manufacturers and innovators must navigate complex supply chains, regulatory compliance, and sustainability considerations while accelerating next-generation product development. The combination of these forces creates both significant opportunities for targeted innovation and acute operational risks for organizations that are slow to adapt. Accordingly, this introduction frames the broader patterns that inform the remainder of the analysis and sets the stage for practical recommendations that align scientific progress with real-world access and commercial viability.

Key systemic shifts in technology, distribution, materials, and regulatory practice that are redefining contraceptive choice and delivery models

Over the last decade, several transformative shifts have redefined the contraceptive landscape, driven by converging advances in technology, consumer behavior, and health system priorities. Long-acting reversible contraception has become more prominent in clinical guidelines and practice, prompting manufacturers to emphasize durability, ease of insertion, and minimized side effects. Concurrently, progress in hormonal and non-hormonal formulations-spanning implantables, injectables, oral systems, transdermal patches, and barrier methods-has broadened therapeutic choices, enabling more personalized care pathways.

Digital and distribution innovations have accelerated change by lowering friction for prescription access and adherence support. Telehealth consultations combined with e-commerce and online pharmacy fulfillment are altering the balance between traditional clinical settings and consumer-facing channels. At the same time, material science improvements, including alternatives to conventional latex products, are creating opportunities to address allergy concerns and enhance user comfort. Regulatory landscapes have adjusted to accommodate these innovations, yet also introduce complexity around clinical endpoints, post-market surveillance, and cross-border distribution. Taken together, these shifts are not incremental; they change how products are developed, marketed, and delivered, forcing stakeholders to rethink clinical engagement, patient education, and supply chain resilience in an increasingly interconnected ecosystem.

Assessing how tariff measures in major markets have reshaped sourcing, materials choices, inventory planning, and access dynamics across contraceptive supply chains

The introduction of tariff measures by a major economy in 2025 created immediate reverberations across global supply chains for contraceptive products and their constituent materials. Manufacturers sourcing raw materials or components from affected jurisdictions faced higher landed costs, prompting rapid reassessment of procurement strategies and supplier diversification. In many cases, contract manufacturers and finished-goods producers began evaluating nearshoring options, dual-sourcing arrangements, and stockpiling approaches to mitigate disruption, which in turn affected lead times and inventory models for hospitals, pharmacies, and e-commerce distributors.

Beyond procurement, tariff-related cost pressures influenced strategic decisions concerning product formulation and material selection. For example, supply chain sensitivities accelerated interest in non-latex alternatives such as nitrile, polyisoprene, and polyurethane for barrier products, as firms sought materials with more robust multi-region supply bases. Regulatory compliance costs and customs delays also introduced friction for time-sensitive product launches and for emergency contraceptives that require rapid distribution channels. Clinicians and health systems experienced operational strain when procurement timelines shifted, while payers and purchasing groups began scrutinizing total cost implications, including the downstream effects on patient access. The aggregate effect has been to heighten the importance of supply chain transparency, contractual flexibility, and strategic sourcing as core competencies for companies operating in the contraceptive arena.

Granular segmentation insights that connect product types, formulations, modes of action, materials, and end-user profiles to actionable development and commercial strategies

Segment-level differentiation offers a pragmatic framework for prioritizing product development and commercial strategies. By Type, the market encompasses emergency contraceptives divided into intrauterine devices and pills, hormonal methods including implantable, injectable, oral and transdermal options, non-hormonal approaches featuring barrier methods as well as herbal choices split into Ayurvedic and homeopathic traditions and natural methods, and permanent solutions such as tubal ligation and vasectomy. These distinctions reveal divergent clinical pathways: long-acting and permanent options tend to engage specialist care and health-system procurement, whereas pills, patches, and barrier methods often interact with broader primary care and retail channels.

Considering Formulation, patch, pill and ring formats carry different adherence and acceptability profiles; within pills, the distinction between monophasic and multiphasic regimens informs counseling and side-effect management. Mode of Action segmentation-preventing implantation, spermicidal action, and suppression of ovulation-connects directly to clinical outcomes and patient education priorities, shaping labeling and safety monitoring. Material Type splits into latex-based and non-latex offerings, with the latter subdivided into nitrile, polyisoprene, and polyurethane, each presenting trade-offs in cost, tactile properties, and allergenicity.

Duration and Usage Frequency segmentation-long-term versus short-term and on-demand versus regular use-highlight pathways for engagement and adherence interventions, while Sales Channel distinctions between offline outlets such as hospital pharmacies and retail pharmacies and online channels including e-commerce platforms and online pharmacies underscore shifting acquisition behaviors. Application differentiates general use from post-coital use, signaling differing urgency and distribution requirements. End-User segmentation recognizes female and male cohorts, with further granularity for females across adolescent, adult, and post-menopausal groups, which affects clinical guidance, marketing tone, and packaging. Together, these segmentation lenses provide a cohesive map for aligning product features, regulatory strategy, and go-to-market execution to specific clinical and consumer needs.

Regional strategic imperatives describing how regulatory diversity, cultural norms, manufacturing hubs, and access models shape contraceptive deployment across global markets

Regional dynamics exert a substantial influence on product adoption, regulatory pathways, and distribution models. In the Americas, a mix of advanced clinical adoption in urban centers and uneven access across rural communities creates a dual imperative: invest in both high-efficacy long-acting options for health-system purchasers and accessible retail and online offerings for broader populations. Payer systems and public health programs shape procurement priorities, and telemedicine expansion continues to alter how prescriptions are issued and fulfilled.

Across Europe, Middle East & Africa, regulatory heterogeneity and cultural diversity require nuanced market entry strategies. Regulatory frameworks in parts of Europe emphasize rigorous clinical evidence and post-market surveillance, while certain countries in the Middle East and Africa prioritize local manufacturing incentives and public-sector distribution. These conditions influence decisions around clinical trial design, labeling, and partnership models. In many markets, cultural attitudes toward contraception and the role of community health workers affect adoption patterns, especially for non-hormonal and herbal alternatives.

The Asia-Pacific region presents a broad spectrum from highly industrialized supply hubs to markets with strong traditional medicine use and distinct consumer preferences. Manufacturing capacity in parts of Asia-Pacific supports global supply chains for materials and finished goods, yet local regulatory expectations and reimbursement practices vary substantially. Traditional herbal practices in some locales create parallel demand channels that companies must understand and engage with respectfully. Overall, regional strategies must balance centralized manufacturing efficiencies with local regulatory compliance and culturally informed commercial approaches to ensure both access and acceptance.

Competitive intelligence and corporate strategies revealing how innovation, supply chain resilience, and digital services are reshaping leadership in contraceptive development

Competitive dynamics favor organizations that combine differentiated clinical assets with resilient supply chains and compelling patient-facing services. Leading companies are investing in next-generation hormonal and non-hormonal formulations, accelerating work on long-acting modalities, and exploring male-targeted agents to broaden addressable markets. Strategic alliances between developers, contract manufacturers, and distribution partners are increasingly common, enabling faster scale-up and broader channel reach while mitigating capital intensity.

Other firms are differentiating through material innovation and user experience redesign, optimizing tactile properties, packaging, and instructions for use to improve acceptability and adherence. Digital capabilities, including telehealth integrations, adherence support tools, and e-pharmacy partnerships, are becoming core competitive levers that drive customer acquisition and retention. At the same time, companies with strong regulatory affairs capabilities and diverse manufacturing footprints are better positioned to absorb policy and tariff-driven shocks. Emerging entrants that combine clinical novelty with agile commercialization models present both competition and opportunity for incumbents seeking acquisition targets or partnerships to fill portfolio gaps. Overall, the competitive landscape is shifting from purely product-centric competition to ecosystem competition where service, supply chain reliability, and regulatory agility matter as much as clinical differentiation.

Tactical and strategic actions for executives to strengthen sourcing, accelerate material innovation, expand digital reach, and align portfolios with segmented user needs

Industry leaders should prioritize several coordinated actions to secure both short-term stability and long-term growth. First, diversifying the supplier base and developing contingency sourcing plans will reduce exposure to trade disruptions and tariff volatility; investing in dual-sourcing and qualified regional suppliers enhances operational flexibility. Second, accelerating development and commercialization of non-latex materials will address allergy concerns and broaden market appeal, while simultaneously reducing concentration risk tied to single material classes. Third, expanding digital channels and telehealth partnerships will capture shifting acquisition behavior and improve adherence through integrated support tools.

In parallel, companies should tailor product portfolios and messaging to specific segments identified earlier, aligning clinical attributes with end-user needs such as adolescent education, adult convenience, or post-menopausal safety considerations. Engaging proactively with regulators and payers to clarify evidence requirements and reimbursement pathways will smooth market entry and reduce launch uncertainty. Finally, embedding sustainability and ethical sourcing into procurement and manufacturing decisions will protect brand reputation and respond to growing stakeholder expectations. These actions, taken together, form a pragmatic roadmap for leaders seeking to balance innovation with operational resilience and customer-centric commercialization.

A rigorous mixed-methods research approach combining stakeholder interviews, literature synthesis, supply chain mapping, and scenario analysis to validate insights

The research underpinning this analysis combined qualitative and quantitative approaches to ensure robustness and practical relevance. Primary research included structured interviews with clinicians, procurement officers, regulatory specialists, and distribution executives to capture first-hand perspectives on clinical adoption, sourcing challenges, and channel dynamics. Secondary sources comprised peer-reviewed clinical literature, regulatory filings, product labels, and publicly available policy documents to validate clinical and safety-related assertions. In addition, supply chain analyses mapped material flows and manufacturing footprints to assess vulnerability to trade policy shifts.

Analytical methods included cross-segmentation synthesis to align product attributes with end-user needs and scenario analysis to examine the implications of policy changes and supply-chain disruptions. Findings were triangulated across data sources and expert review to minimize bias and enhance credibility. Limitations of the methodology include variability in region-level data quality and the evolving nature of regulatory guidance, which necessitate periodic updates to maintain relevance. Ethical considerations guided the engagement with clinical experts and respect for cultural contexts when discussing traditional and herbal contraceptive practices. Together, these methods produced a defensible framework for the insights and recommendations presented in this report.

Summative conclusions that translate the evolving technological, regulatory, and supply chain dynamics into pragmatic strategic priorities for stakeholders

In closing, the contraceptive landscape is undergoing meaningful transformation driven by technological progress, evolving distribution channels, materials innovation, and policy dynamics that together influence clinical practice and consumer behavior. Effective strategies will combine clinical differentiation with operational resilience-diversifying suppliers, embracing non-latex materials where appropriate, and integrating digital services to meet users where they seek care. Regional nuances and segmentation layers call for tailored approaches that respect local regulatory and cultural contexts while leveraging global manufacturing strengths.

Stakeholders that act decisively to align product portfolios with clearly defined end-user needs, while strengthening supply chain transparency and regulatory engagement, will be best positioned to capture long-term value. The insights and recommendations offered here are designed to help executives, clinical leaders, and commercial teams convert complexity into opportunity, supporting decisions that improve access, enhance user experience, and sustain innovation in a rapidly changing environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Contraceptive Market, by Type

  • 8.1. Emergency Contraceptives
    • 8.1.1. IUDs
    • 8.1.2. Pills
  • 8.2. Hormonal
    • 8.2.1. Implantable Contraceptives
    • 8.2.2. Injectable Contraceptives
    • 8.2.3. Oral Contraceptives
    • 8.2.4. Transdermal Contraceptives
  • 8.3. Non-Hormonal
    • 8.3.1. Barrier Methods
    • 8.3.2. Herbal Contraceptives
      • 8.3.2.1. Ayurvedic
      • 8.3.2.2. Homeopathic
    • 8.3.3. Natural Methods
  • 8.4. Permanent
    • 8.4.1. Tubal Ligation
    • 8.4.2. Vasectomy

9. Contraceptive Market, by Formulation

  • 9.1. Patch
  • 9.2. Pill
    • 9.2.1. Monophasic
    • 9.2.2. Multiphasic
  • 9.3. Ring

10. Contraceptive Market, by Mode Of Action

  • 10.1. Prevent Implantation
  • 10.2. Spermicidal Action
  • 10.3. Suppress Ovulation

11. Contraceptive Market, by Material Type

  • 11.1. Latex-Based
  • 11.2. Non-Latex
    • 11.2.1. Nitrile
    • 11.2.2. Polyisoprene
    • 11.2.3. Polyurethane

12. Contraceptive Market, by Duration

  • 12.1. Long-Term
  • 12.2. Short-Term

13. Contraceptive Market, by Usage Frequency

  • 13.1. On-Demand
  • 13.2. Regular Use

14. Contraceptive Market, by Sales Channel

  • 14.1. Offline
    • 14.1.1. Hospital Pharmacy
    • 14.1.2. Pharmacy
  • 14.2. Online
    • 14.2.1. E-Commerce Platforms
    • 14.2.2. Online Pharmacy

15. Contraceptive Market, by Application

  • 15.1. General Use
  • 15.2. Post-Coital Use

16. Contraceptive Market, by End-User

  • 16.1. Female
    • 16.1.1. Adolescent
    • 16.1.2. Adult
    • 16.1.3. Post-Menopausal
  • 16.2. Male

17. Contraceptive Market, by Region

  • 17.1. Americas
    • 17.1.1. North America
    • 17.1.2. Latin America
  • 17.2. Europe, Middle East & Africa
    • 17.2.1. Europe
    • 17.2.2. Middle East
    • 17.2.3. Africa
  • 17.3. Asia-Pacific

18. Contraceptive Market, by Group

  • 18.1. ASEAN
  • 18.2. GCC
  • 18.3. European Union
  • 18.4. BRICS
  • 18.5. G7
  • 18.6. NATO

19. Contraceptive Market, by Country

  • 19.1. United States
  • 19.2. Canada
  • 19.3. Mexico
  • 19.4. Brazil
  • 19.5. United Kingdom
  • 19.6. Germany
  • 19.7. France
  • 19.8. Russia
  • 19.9. Italy
  • 19.10. Spain
  • 19.11. China
  • 19.12. India
  • 19.13. Japan
  • 19.14. Australia
  • 19.15. South Korea

20. United States Contraceptive Market

21. China Contraceptive Market

22. Competitive Landscape

  • 22.1. Market Concentration Analysis, 2025
    • 22.1.1. Concentration Ratio (CR)
    • 22.1.2. Herfindahl Hirschman Index (HHI)
  • 22.2. Recent Developments & Impact Analysis, 2025
  • 22.3. Product Portfolio Analysis, 2025
  • 22.4. Benchmarking Analysis, 2025
  • 22.5. Abbvie, Inc.
  • 22.6. Afaxys, Inc.
  • 22.7. Agile Therapeutics
  • 22.8. Bayer AG
  • 22.9. China Resources (Group) Co., LTD.
  • 22.10. Church & Dwight Co., Inc.
  • 22.11. Cupid Limited
  • 22.12. Helm AG
  • 22.13. Johnson & Johnson Services, Inc.
  • 22.14. Organon Group of Companies
  • 22.15. Pfizer Inc.
  • 22.16. Veru, Inc.
  • 22.17. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CONTRACEPTIVE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CONTRACEPTIVE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CONTRACEPTIVE MARKET SIZE, BY DURATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CONTRACEPTIVE MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. UNITED STATES CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 17. CHINA CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CONTRACEPTIVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IUDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONTRACEPTIVE MARKET SIZE, BY IMPLANTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CONTRACEPTIVE MARKET SIZE, BY INJECTABLE CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TRANSDERMAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CONTRACEPTIVE MARKET SIZE, BY BARRIER METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CONTRACEPTIVE MARKET SIZE, BY AYURVEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOMEOPATHIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NATURAL METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CONTRACEPTIVE MARKET SIZE, BY TUBAL LIGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CONTRACEPTIVE MARKET SIZE, BY VASECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MONOPHASIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MULTIPHASIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CONTRACEPTIVE MARKET SIZE, BY RING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PREVENT IMPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SPERMICIDAL ACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SUPPRESS OVULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LATEX-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CONTRACEPTIVE MARKET SIZE, BY NITRILE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYISOPRENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POLYURETHANE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CONTRACEPTIVE MARKET SIZE, BY LONG-TERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SHORT-TERM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ON-DEMAND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGULAR USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CONTRACEPTIVE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CONTRACEPTIVE MARKET SIZE, BY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CONTRACEPTIVE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GENERAL USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-COITAL USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CONTRACEPTIVE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CONTRACEPTIVE MARKET SIZE, BY POST-MENOPAUSAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CONTRACEPTIVE MARKET SIZE, BY MALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CONTRACEPTIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 220. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 222. LATIN AMERICA CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPE CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPE CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 280. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 282. MIDDLE EAST CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 283. AFRICA CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 284. AFRICA CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. AFRICA CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 286. AFRICA CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 287. AFRICA CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 288. AFRICA CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 289. AFRICA CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 290. AFRICA CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 291. AFRICA CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 292. AFRICA CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 293. AFRICA CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. AFRICA CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 295. AFRICA CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 296. AFRICA CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 297. AFRICA CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. AFRICA CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 299. AFRICA CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 300. AFRICA CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 301. AFRICA CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 302. AFRICA CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 320. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 323. GLOBAL CONTRACEPTIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 324. ASEAN CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 325. ASEAN CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. ASEAN CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 327. ASEAN CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 328. ASEAN CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 329. ASEAN CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 330. ASEAN CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 331. ASEAN CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 332. ASEAN CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 333. ASEAN CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 334. ASEAN CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 335. ASEAN CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 336. ASEAN CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 337. ASEAN CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 338. ASEAN CONTRACEPTIVE MARKET SIZE, BY SALES CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 339. ASEAN CONTRACEPTIVE MARKET SIZE, BY OFFLINE, 2018-2032 (USD MILLION)
  • TABLE 340. ASEAN CONTRACEPTIVE MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 341. ASEAN CONTRACEPTIVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 342. ASEAN CONTRACEPTIVE MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 343. ASEAN CONTRACEPTIVE MARKET SIZE, BY FEMALE, 2018-2032 (USD MILLION)
  • TABLE 344. GCC CONTRACEPTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 345. GCC CONTRACEPTIVE MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. GCC CONTRACEPTIVE MARKET SIZE, BY EMERGENCY CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 347. GCC CONTRACEPTIVE MARKET SIZE, BY HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 348. GCC CONTRACEPTIVE MARKET SIZE, BY NON-HORMONAL, 2018-2032 (USD MILLION)
  • TABLE 349. GCC CONTRACEPTIVE MARKET SIZE, BY HERBAL CONTRACEPTIVES, 2018-2032 (USD MILLION)
  • TABLE 350. GCC CONTRACEPTIVE MARKET SIZE, BY PERMANENT, 2018-2032 (USD MILLION)
  • TABLE 351. GCC CONTRACEPTIVE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 352. GCC CONTRACEPTIVE MARKET SIZE, BY PILL, 2018-2032 (USD MILLION)
  • TABLE 353. GCC CONTRACEPTIVE MARKET SIZE, BY MODE OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 354. GCC CONTRACEPTIVE MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 355. GCC CONTRACEPTIVE MARKET SIZE, BY NON-LATEX, 2018-2032 (USD MILLION)
  • TABLE 356. GCC CONTRACEPTIVE MARKET SIZE, BY DURATION, 2018-2032 (USD MILLION)
  • TABLE 357. GCC CONTRACEPTIVE MARKET SIZE, BY USAGE FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 358.